Nippon India Pharma Fund - Growth
- Sector - Healthcare
- Equity
- Very High Risk
Rating:
Key Metrics
Aum
₹9,279.11 Cr
Expense Ratio
1.85%
Exit Load
1.00%
Min. Investment
₹5,000.00
Min. SIP
₹100.00
Launch Date
5 Jun 2004
CAGR Returns
| Period | Absolute(%) | Annualised(%) |
|---|---|---|
| 1 Month | +0.18% | -- |
| 3 Months | +7.18% | -- |
| 6 Months | +12.01% | -- |
| 1 Year | +11.41% | +11.41% |
| 2 Years | -- | +4.85% |
| 3 Years | +63.82% | +17.88% |
| 5 Years | +82.47% | +12.78% |
| Since Launch | +5620.41% | +19.94% |
Holdings as on 8 Sep 2026
| Name | Value (₹Cr) | Holding % |
|---|---|---|
| Sun Pharmaceutical Industries | 1,235.38 | 13.31 |
| Lupin | 672.34 | 7.25 |
| Divi's Laboratories | 604.81 | 6.52 |
| Cipla | 559.09 | 6.03 |
| Apollo Hospitals Enterprise | 491.56 | 5.30 |
| Dr Reddy's Laboratories | 464.96 | 5.01 |
| Mankind Pharma | 346.84 | 3.74 |
| Sai Life Sciences | 336.11 | 3.62 |
| Ajanta Pharma | 316.70 | 3.41 |
| Max Healthcare Institute | 292.00 | 3.15 |
Morning Star Rating
Rating:
Risk
Return
Risk & Volitility
0.81
Sharpe Ratio
14.76%
Std. Deviation
5.26%
Tracking Error
5.93%
Alpha
0.89
Beta
Peer Comparison
| Fund Name | 1Y | 3Y | 5Y |
|---|---|---|---|
| SBI Healthcare Opportunities Fund Regular Growth | +20.55% | +23.04% | +17.34% |
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth | +8.13% | +21.35% | +15.07% |
| Mirae Asset Healthcare Fund Regular Growth | +19.18% | +21.1% | +14.04% |
| DSP Healthcare Fund Regular Growth | +16.39% | +20.94% | +13.86% |
| Nippon India Pharma Fund - Growth | +11.41% | +17.88% | +12.78% |
Results are calculated on CAGR basis
About Fund
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
The Nippon India Pharma Fund - Growth has an AUM of 9279.11 crores & has delivered CAGR of 12.78 in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.85%. The minimum investment in Nippon India Pharma Fund - Growth is Rs 5000 and the minimum SIP is Rs 100.
As per morningstar the risk & return rating of the fund are Medium & Exceptional respectively.
The fund has a present cash holding of %. The top holdings of the fund include Sun Pharmaceutical Industries, Lupin, Divi's Laboratories, Cipla.
The major sectors where the fund is invested are Biotechnology & Drugs, Healthcare Facilities, Major Drugs, Retail (Drugs).
Some of the similar funds are SBI Healthcare Opportunities Fund Regular Growth, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth, Mirae Asset Healthcare Fund Regular Growth, DSP Healthcare Fund Regular Growth, Nippon India Pharma Fund - Growth. Nippon India Pharma Fund - Growth has a sharpe ratio of 0.81 & a standard deviation of 14.76%.
FAQs
According to the morning star rating Nippon India Pharma Fund - Growth has a Medium risk & Exceptional return.
Nippon India Pharma Fund - Growth is managed by Sailesh Raj Bhan,Kinjal Desai,Amber Singhania.
The expense ratio of Nippon India Pharma Fund - Growth is 1.85%.
The 5 year annualized return on Nippon India Pharma Fund - Growth is 12.78% & it has generated 11.41% in the last 1 year.
The minimum investment in Nippon India Pharma Fund - Growth is 5000 Rs.
Nippon India Pharma Fund - Growth has an AUM of 9279.11 crores.
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.